Context Although most primary cancers of the lung carry a heavy mutational load and will
potentially present many “nonself” antigens to the immune system, there are a wide range of …

Immunohistochemical assays for programmed cell death ligand 1 (PD-L1) expression in non–
small cell lung cancer (NSCLC) are either required or recommended to guide therapy with …

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–
programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small …

9017 Background: Temporal and spatial heterogeneity of PD-L1 has been reported.
However, its impact on clinical benefit from immune checkpoint inhibitor (ICI) has not been …

Introduction Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)
or its ligand, PD-L1, have gained momentum in the treatment of non–small cell lung cancer …

Abstract Background Circulating tumor cells (CTCs) are a promising source of biological
information in cancer. Data correlating PD-L1 expression in CTCs with patients' response to …

Biomarkers for immune checkpoint inhibitors in advanced nons... : Current Opinion in
Oncology Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer …

Immune checkpoint inhibition with anti-PD-1 therapy has been notably successful in non-
small cell lung cancer (NSCLC) and changed standard practice in multiple settings …

Background Testing for tumor programmed death ligand-1 (PD-L1) expression was initially
developed with histology specimens in non-small cell lung cancer (NSCLC). However …

Background We correlated the tumor proportion score (TPS) of programmed cell death
ligand 1 (PD‐L1, SP263 or 22C3) expression with the disease control rate (DCR, partial …